scholarly journals Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer

2006 ◽  
Vol 118 (10) ◽  
pp. 2636-2638 ◽  
Author(s):  
Hideaki Yahata ◽  
Mami Saito ◽  
Toshiaki Sendo ◽  
Yoshinori Itoh ◽  
Mayako Uchida ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Hypersensitivity Reactions ◽  
Prophylactic Effect ◽  
Antiallergic Agent

scholarly journals Hypersensitivity reactions to antineoplastic agents in BRCA-mutated ovarian cancer (OC) patients: a single centre experience

2016 ◽  
Vol 27 ◽  
pp. vi298
Author(s):  
E. Maccaroni ◽  
R. Bracci ◽  
R. Giampieri ◽  
F. Bianchi ◽  
L. Belvederesi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Antineoplastic Agents ◽  
Hypersensitivity Reactions ◽  
Single Centre ◽  
Single Centre Experience

Cisplatin may be a Valid Alternative Approach in Ovarian Carcinoma with Carboplatin Hypersensitivity. Report of Three Cases

2003 ◽  
Vol 89 (3) ◽  
pp. 311-313 ◽  
Author(s):  
Massimo Libra ◽  
Roberto Sorio ◽  
Angela Buonadonna ◽  
Massimiliano Berretta ◽  
Peter Stefanovski ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Standard Treatment ◽  
Chemotherapeutic Agent ◽  
Advanced Ovarian Cancer ◽  
Hypersensitivity Reactions ◽  
Toxicity Profile ◽  
Alternative Approach ◽  
Successful Resolution ◽  
Carboplatin Hypersensitivity ◽  
Favorable Toxicity Profile

Platinum-based therapy is considered the standard treatment for patients with advanced ovarian cancer. Carboplatin has a more favorable toxicity profile than cisplatin; however, hypersensitivity reactions to carboplatin have been reported occasionally. We reviewed 112 cases of ovarian cancer treated with carboplatin at our institute to identify the hypersensitivity reactions to this chemotherapeutic agent. Hypersensitivity reactions were documented in nine cases (8%). No deaths occurred, but the reactions were judged severe in three of the 112 patients (2.6%). In our own experience with patients showing idiosyncrasy to carboplatin we observed successful resolution after retreatment with cisplatin. Since patients who relapse after initial treatment with carboplatin often respond to it a second time, it is important to continue this treatment.

Hypersensitivity Reactions to Intraperitoneal Administration of Carboplatin in Ovarian Cancer: The First Report of a Case

1999 ◽  
Vol 72 (3) ◽  
pp. 431-432 ◽  
Author(s):  
Ken-ichi Shukunami ◽  
Tetsuji Kurokawa ◽  
Yuka Kawakami ◽  
Makoto Kubo ◽  
Fumikazu Kotsuji
Keyword(s):  
Ovarian Cancer ◽  
Intraperitoneal Administration ◽  
Hypersensitivity Reactions ◽  
First Report

Hypersensitivity Reactions in Ovarian Cancer Patients Receiving Paclitaxel

1999 ◽  
Vol 11 (5) ◽  
pp. 407-409 ◽  
Author(s):  
G. Cormio ◽  
G. Di Vagno ◽  
G.A. Melilli ◽  
A. Cazzolla ◽  
G. Di Gesù ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Hypersensitivity Reactions

Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients

2002 ◽  
Vol 22 (3) ◽  
pp. 312-313 ◽  
Author(s):  
O. Lehoczky ◽  
Andrea Bagaméri ◽  
J. Udvary ◽  
T. Pulay
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Hypersensitivity Reactions ◽  
Paclitaxel Treatment
Sign in / Sign up

Export Citation Format

Share Document